 23andMe Holding Co. is the leading direct-to-consumer genetic testing company entering drug development with data on 11.3M Genotyped Customers and 696M in SPAC funding. 23andMes core products include a suite of D2C genetic reports covering ancestry, genetic health risks, carrier status, and medication responses and 40 programs 2 clinical-stage for therapeutic development. 